TITLE

Sildenafil is useful in pulmonary arterial hypertension

AUTHOR(S)
Karadi, R. L.
PUB. DATE
February 2006
SOURCE
Thorax;Feb2006, Vol. 61 Issue 2, p176
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
The abstract of the study "Sildenafil is useful in pulmonary arterial hypertension," by N. Galie, H.A. Ghofrani, A. Tarbicki and colleagues, is presented. The multicenter, double blind, placebo controlled study was performed in 278 patients with pulmonary arterial hypertension. The patients were randomized into four treatment groups.
ACCESSION #
19787756

 

Related Articles

  • Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. Galiè, Nazzareno; Ghofrani, Hossein A.; Torbicki, Adam; Barst, Robyn J.; Rubin, Lewis J.; Badesch, David; Fleming, Thomas; Parpia, Tamiza; Burgess, Gary; Branzi, Angelo; Grimminger, Friedrich; Kurzyna, Marcin; Simonneau, Gérald // New England Journal of Medicine;11/17/2005, Vol. 353 Issue 20, p2148 

    Background: Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate–mediated relaxation and growth inhibition of vascular smooth-muscle cells, including those in the lung. Methods: In...

  • Ambrisentan. Croxtall, Jamie D.; Keam, Susan J. // Drugs;2008, Vol. 68 Issue 15, p2195 

    â–´ Elevated endothelin (ET)-1 levels are strongly correlated with the pathogenesis and prognosis of pulmonary arterial hypertension (PAH). Ambrisentan is an orally active, highly selective ETA receptor antagonist with >4000-fold higher selectivity over the ETB receptor. â–´ In two...

  • Nattokinase for Hypertension. Gaby, Alan R. // Townsend Letter;Jun2009, Issue 311, p39 

    The article presents a commentary about a study on nattokinase as a treatment for mild hypertension. Nattokinase is compared with placebo. The mechanism of action of nattokinase as an antihypertensive agent is emphasized. The significance of nattokinase treatment on plasma renin activity is...

  • Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. Gueyffier, F; Subtil, F; Bejan-Angoulvant, T; Zerbib, Y; Baguet, J P; Boivin, J M; Mercier, A; Leftheriotis, G; Gagnol, J P; Fauvel, J P; Giraud, C; Bricca, G; Maucort-Boulch, D; Erpeldinger, S // Journal of Human Hypertension;Jan2015, Vol. 29 Issue 1, p22 

    Current antihypertensive strategies do not take into account that individual characteristics may influence the magnitude of blood pressure (BP) reduction. Guidelines promote trial-and-error approaches with many different drugs. We conducted the Identification of the Determinants of the Efficacy...

  • Clinical Trials Update. Torres, Fernando; Levine, Deborah Jo // Advances in Pulmonary Hypertension;Summer2011, Vol. 10 Issue 3, p137 

    The article provides an update on clinical trials that explore therapies for pulmonary arterial hypertension (PAH). It provides an overview of the oral prostacyclin trials, noting that the search for an oral prostacyclin to treat PAH dates back to 2003. Critical topics being discussed include...

  • Are hypertension drugs really saving lives? Kendrick, Malcolm // Pulse;2/19/2005, Vol. 65 Issue 7, p68 

    The article reports on whether hypertension drugs can save lives. Perhaps the most misleading terminology of all is the current trend to talk about lives saved' by treatment. In reality it is only possible to state that a life has been saved if a disease has been fully cured and will never...

  • The risks associated with short-term placebo-controlled antihypertensive clinical trials: a descriptive meta-analysis. DeFelice, A; Willard, J; Lawrence, J; Hung, J; Gordon, M A; Karkowsky, A; Targum, S; Throckmorton, D C; Girton, J; Stertz, B; Glasser, S P; Lipicky, R J // Journal of Human Hypertension;Oct2008, Vol. 22 Issue 10, p659 

    Short-term (4–8 weeks) placebo-controlled trials are used to evaluate new antihypertensive drug treatment. To evaluate the consequences of such practice, a descriptive meta-analysis was conducted, consisting of blinded review of original case report forms for all patients who died or left...

  • Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement. Gandhi, Hemang; Shah, Bipin; Patel, Ramesh; Toshani, Rajesh; Pujara, Jigisha; Kothari, Jignesh; Shastri, Naman // Indian Journal of Pharmacology;May/Jun2014, Vol. 46 Issue 3, p281 

    Aim: Long standing mitral valve disease is usually associated with severe pulmonary hypertension. Perioperative pulmonary hypertension is a risk factor for right ventricular (RV) failure and a cause for morbidity and mortality in patients undergoing mitral valve replacement. Phosphodiesterase 5...

  • A Double-blind Placebo-controlled Evaluation of the Effect of Topical Sildenafil on Erectile Dysfunction. Yonessi, Mehdi; Saeedi, Madjid // Journal of Applied Research;2005, Vol. 5 Issue 2, p289 

    Several adverse effects have been reported with use of oral sildenafil in the treatment of erectile dysfunction (ED). In this study, a formulation of sildenafil topical gel was compared with sildenafil tablet in a randomized, double-blind, prospective, placebo-controlled clinical trial. A total...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics